Molecular Formula | C21H22N4O3 |
Molar Mass | 378.42 |
Density | 1.29±0.1 g/cm3(Predicted) |
Boling Point | 554.7±50.0 °C(Predicted) |
pKa | 14.76±0.40(Predicted) |
Use | Feinelidone (Finerenone,BAY 94-8862) is a non-steroidal selective mineralocorticoid receptor antagonist, which has been shown to block the harmful effects caused by excessive activation of mineralocorticoid receptors in preclinical studies. In diabetic patients, mineralocorticoid receptor overactivation is believed to lead to chronic kidney disease progression and cardiovascular damage, which may be driven by factors such as metabolism, hemodynamics, or inflammation and fibrosis. Finerenone (FIN, BAY 94-8862) is a highly selective, orally active non-steroidal antagonist of mineralocorticoid receptor (MR) with an IC50 value of 18 nM. Finerenone has the potential to study heart and kidney diseases such as type 2 diabetes and chronic kidney disease. |
In vitro study | In vitro, Finerenone dose-dependently reduces aldosterone-induced smooth muscle cell (SMC) proliferation and prevents aldosteroneinduced endothelial cell (EC) apoptosis. Finerenone significantly reduces apoptosis of ECs and simultaneously attenuates SMC proliferation, resulting in accelerated endothelial healing and reduced neointima formation of the injured vessels. |
In vivo study | Finerenone improves endothelial dysfunction through an enhancement in NO bioavailability and a decrease in superoxide anion levels due to an upregulation in SOD activity. This is associated with an increase in renal SOD activity and a reduction of albuminuria. |
Nature:
1. Feneridone is a solid compound that is a white to light yellow crystalline solid at room temperature.
2. It has low solubility in water, but good solubility in some organic solvents.
Method:
The preparation method of phenanthrone is usually achieved through chemical synthesis, and the specific synthesis route may vary, but usually involves multiple reactions to convert the raw material into the target product.
Security information:
1. Attention should be paid to possible side effects and safety issues when using phenirazone.
2. According to existing research and clinical trial data, phenirazone is generally safe and well tolerated, but there may still be some adverse reactions, such as dizziness, fatigue, headache, etc.